Search - tctmd.com

Displaying 601 - 620 of 671

Presentation

Accelerated Platelet Inhibition by Switching from Atorvastatin to a Non-CYP3A4-Metabolized Statin

Presenter: Y. Park

April 24, 2012

$Unfractionated, Low Molecular Weight Heparins, and Xa Inhibitors in ACS and PCI, With and Without GP IIb/IIIa Inhibitors$

Presentation Fellows 2012

Unfractionated, Low Molecular Weight Heparins, and Xa Inhibitors in ACS and PCI, With and Without GP IIb/IIIa Inhibitors

Presenter: George Dangas

April 22, 2012

Presentation Fellows 2012

Platelet Function Testing, Genomics, and Antiplatelet Agent Resistance

Presenter: Deepak Bhatt

April 22, 2012

Presentation Fellows 2012

Oral Antithrombin and Xa Inhibitors for ACS and PCI

Presenter: Michael Ezekowitz

April 22, 2012

Presentation Fellows 2012

Oral Antiplatelet Agents in PCI and ACS

Presenter: Roxana Mehran

April 22, 2012

Presentation Fellows 2012

Bivalirudin in ACS and PCI

Presenter: Gregg Stone

April 22, 2012

Presentation

A Randomized Trial of Prasugrel vs. Clopidogrel in Patients with High Platelet Reactivity on Clopidogrel After Elective PCI with DES

Presenter: Dietmar Trenk

April 18, 2012

Presentation GI2 2012

Dual Antiplatelet Therapy Post PCI: Challenging the Guidelines

Presenter: Fausto Feres

April 13, 2012

Presentation

Relationship Between CYP2C19 Polymorphisms and Ischemic and Bleeding Outcomes in Stable Outpatients

Presenter: Deepak L. Bhatt

April 09, 2012

Presentation

Does Aggressive Statin Therapy Reduce Coronary Atherosclerotic Plaque Lipid Content?

Presenter: Annapoorna S. Kini

April 04, 2012

Presentation

Short- vs. Long-term Duration of Dual Antiplatelet Therapy (DAPT) After Coronary Stenting

Presenter: Marco Valgimigli

April 02, 2012

Presentation

RAPID GENE: Point-of-Care Genetic Testing for Personalization of Antiplatelet Treatment

Presenter: J.D. Roberts

March 29, 2012

Presentation ACC 2012

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Presenter: Myeong-Ki Hong

March 25, 2012

Presentation ACC 2012

RESET Study: Pharmacodynamic Effects of Switching Therapy in PCI Patients with High on Treatment Platelet Reactivity and Genotype Variation: High Clopidogrel Dose versus Prasugrel

Presenter: Gennaro Sardella

March 24, 2012

Presentation ACC 2012

First Pharmacogenomic Analysis Using Whole Exome Sequencing to Identify Novel Genetic Determinants of Clopidogrel

Presenter: Matthew Price

March 24, 2012

Presentation ACC 2012

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

Presenter: Hyo-Soo Kim

March 24, 2012

Presentation PCI Outcomes 2012

PCI in NSTEMI and STEMI: Essentials of Pharmacology

Presenter: C. Michael Gibson

March 23, 2012

Presentation PCI Outcomes 2012

Optimizing Pharmacology Before, During and After PCI

Presenter: E. Magnus Ohman

March 23, 2012

Presentation

El Tabaquismo se asocia a un Efecto Dosis-Respuesta en Pacientes tratados con Clopidogrel con Diabetes Mellitus y EAC

Presenter: M. Ueno

March 19, 2012

Presentation

Cigarette Smoking Associated with a Dose-Response Effect in Clopidogrel-Treated Patients with Diabetes Mellitus and CAD

Presenter: M. Ueno

March 19, 2012

Advertisement

Accelerated Platelet Inhibition by Switching from Atorvastatin to a Non-CYP3A4-Metabolized Statin

Unfractionated, Low Molecular Weight Heparins, and Xa Inhibitors in ACS and PCI, With and Without GP IIb/IIIa Inhibitors

Platelet Function Testing, Genomics, and Antiplatelet Agent Resistance

Oral Antithrombin and Xa Inhibitors for ACS and PCI

Oral Antiplatelet Agents in PCI and ACS

Bivalirudin in ACS and PCI

A Randomized Trial of Prasugrel vs. Clopidogrel in Patients with High Platelet Reactivity on Clopidogrel After Elective PCI with DES

Dual Antiplatelet Therapy Post PCI: Challenging the Guidelines

Relationship Between CYP2C19 Polymorphisms and Ischemic and Bleeding Outcomes in Stable Outpatients

Does Aggressive Statin Therapy Reduce Coronary Atherosclerotic Plaque Lipid Content?

Short- vs. Long-term Duration of Dual Antiplatelet Therapy (DAPT) After Coronary Stenting

RAPID GENE: Point-of-Care Genetic Testing for Personalization of Antiplatelet Treatment

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

RESET Study: Pharmacodynamic Effects of Switching Therapy in PCI Patients with High on Treatment Platelet Reactivity and Genotype Variation: High Clopidogrel Dose versus Prasugrel

First Pharmacogenomic Analysis Using Whole Exome Sequencing to Identify Novel Genetic Determinants of Clopidogrel

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

PCI in NSTEMI and STEMI: Essentials of Pharmacology

Optimizing Pharmacology Before, During and After PCI

El Tabaquismo se asocia a un Efecto Dosis-Respuesta en Pacientes tratados con Clopidogrel con Diabetes Mellitus y EAC

Cigarette Smoking Associated with a Dose-Response Effect in Clopidogrel-Treated Patients with Diabetes Mellitus and CAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content